SCHEMBL6709752

SCHEMBL6709752

C#CCCCC(C)CCCCCCCCC

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ACE2 Q9BYF1 1/20 0.47
OPRM1 P35372 1/20 0.39
PRKD3 O94806 1/20 0.38
PRKCG P05129 1/20 0.38
PRKCB P05771 1/20 0.38
PRKCA P17252 1/20 0.38
PRKCH P24723 1/20 0.38
PRKCI P41743 1/20 0.38
PRKCE Q02156 1/20 0.38
PRKCQ Q04759 1/20 0.38
PRKCZ Q05513 1/20 0.38
PRKCD Q05655 1/20 0.38
PRKD1 Q15139 1/20 0.38
SPHK1 Q9NYA1 1/20 0.38
USP2 O75604 1/20 0.37
CYP3A4 P08684 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
LMNA P02545 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9006948 0.86 TSHR (0.39) ACE2USP2CYP3A4SMN1; SMN2LMNA
SCHEMBL8179631 0.84 LMNA (0.39) ACE2OPRM1USP2CYP3A4SMN1; SMN2
SCHEMBL28162919 0.82 ACE2 (0.36) ACE2OPRM1LMNA
SCHEMBL6760264 0.81 ACE2 (0.62) ACE2OPRM1PRKD3PRKCGPRKCB
SCHEMBL20506756 0.81 ACE2 (0.62) ACE2OPRM1PRKD3PRKCGPRKCB
SCHEMBL21086628 0.81 ACE2 (0.62) ACE2OPRM1PRKD3PRKCGPRKCB
SCHEMBL20506768 0.81 ACE2 (0.62) ACE2OPRM1PRKD3PRKCGPRKCB
SCHEMBL20835139 0.81 ACE2 (0.62) ACE2OPRM1PRKD3PRKCGPRKCB
SCHEMBL20506761 0.81 ACE2 (0.62) ACE2OPRM1PRKD3PRKCGPRKCB
SCHEMBL9488357 0.81 ACE2 (0.62) ACE2OPRM1PRKD3PRKCGPRKCB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6835846-B2 The present invention provides an aliphatic compound represented by the following formula (I) or pharmacologically acceptable salts thereof: the aliphatic compound being an optical isomer of the (2R,3S,2'S) configuration when the MARUHA CORPORATION (JP) 2004-12-28 US disclosed
US-20040014816-A1 Novel aliphatic compounds, process for their preparation and their usage MARUHA NICHIRO SEAFOODS, INC. (JP) 2004-01-22 US disclosed
EP-1325904-A1 NOVEL ALIPHATIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THEIR USAGE Maruha Corporation (JP) 2003-07-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014816-A1 Novel aliphatic compounds, process for their preparation and their usage CPT1B, ACSS2, CERS2 ACE2 1437/4885OPRM1 2653/4885PRKD3 3376/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.